Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Pharma 2017: 3Cs And D (Disruption)?

Executive Summary

2017 is predicted to be action-packed for the Indian pharmaceutical industry. Compliance-related issues, consolidation, a potential pick-up in collaborations between innovator and local firms, and activity around Indian biosimilars on the global stage, are just some of the things to keep an eye out for. Meanwhile, India’s demonetization move and the Trump presidency will be reminders to expect the unexpected, say experts.

You may also be interested in...

India's 'Haphazard' Ban On 344 Combos Struck Down But Will Science Prevail?

An Indian court has struck down a controversial government order aimed at weeding out over 300 irrational fixed dose combinations, bringing some relief to the pharma industry, although the case seems far from over. The jury appears to be still out on the therapeutic rationale of some of the combinations, raising questions around patient interests.

Banknote Ban Boosts Business At India E-Pharmacy Start-Ups

Other retailers may be feeling the pain, but India’s nascent e-pharmacy sector says business is better than ever since the country’s prime minister outlawed 86% of the cash in circulation to address tax avoidance.

'Upheavals' In Store As India Set To Mandate Marketing Code

India's uniform code for pharmaceuticals marketing practices, so far voluntary in nature, appears to be on course to becoming "statutory" and "mandatory", signaling some potential short-term turbulence in the growing domestic market.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts